Presence of Aberrant Tumor-Reactive Immunoglobulins in the Circulation of Patients with Ovarian Cancer
- 1 April 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 81 (1) , 71-76
- https://doi.org/10.1006/gyno.2000.6102
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patientsCancer Immunology, Immunotherapy, 1998
- Immunologic characterization of tumor markers in human ovarian cancer cell linesJournal of the Society for Gynecologic Investigation, 1996
- 1975–1995 Revised anti-cancer serological response: Biological significance and clinical implicationsAnnals of Oncology, 1996
- Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.Proceedings of the National Academy of Sciences, 1995
- Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patientsThe Lancet, 1995
- Antigens and Antibodies in Malignant MelanomaTumor Biology, 1994
- Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.The Journal of Experimental Medicine, 1991
- Identification of Antigenic Components Recognized by “Membrane-Bound” Antibodies From Ovarian Cancer PatientsAmerican Journal of Reproductive Immunology, 1984
- “Membrane‐Associated” Immunoglobulins in Cyst and Ascites Fluids of Ovarian Cancer Patients*American Journal of Reproductive Immunology, 1983
- Quantitation of peroxidase-antibody binding to membrane fragments using column chromatographyAnalytical Biochemistry, 1979